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Introduction
Prolonged pregnancy is a common indication for 
the induction of labor [1]. Gestational age exceeding
41 weeks is associated with higher maternal and peri-
natal morbidities, and termination of the pregnancy is
preferred [2–6].
The rate of labor induction in America doubled from
1990 to 1998, from approximately 10% to 20% [7].
Prostaglandins can be administered at various doses
and by different routes of administration. They have a
twofold action that includes stimulation of myometrial
contractility, as well as cervical ripening [8–10].
Several studies have demonstrated a higher efficacy
of vaginally administered misoprostol compared with
vaginal dinoprostone, in terms of both cervical ripen-
ing and labor induction [11–13]. A review of 45 ran-
domized studies concluded that vaginal misoprostol
(25–100 μg) was more effective than oxytocin or dino-
prostone at the usual recommended doses used for
induction, but was associated with increased rates of
uterine hyperstimulation, both with and without asso-
ciated fetal heart rate changes, as well as with meconium-
stained fluid [14].
However, interpretation of most previous studies
comparing misoprostol and dinoprostone for the
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SUMMARY
Objective: To compare the efficacy and safety of intravaginal misoprostol and dinoprostone for elective induc-
tion of labor in nulliparous women with an unfavorable cervix.
Materials and Methods: A quasi-experimental study was conducted in Bahawal Victoria Hospital, Bahawalpur,
Pakistan, from July 1, 2005 to August 31, 2006. A total of 120 primigravid women with gestational ages of > 40
weeks to < 42 weeks were divided into two groups. Group A (n = 60) was given 50 μg of misoprostol and Group
B (n = 60) was given 3 mg of dinoprostone every 6 hours, for a maximum of three doses.
Results: The induction to onset of significant uterine contractions and delivery intervals were lower in Group A
than in Group B (6.1 vs. 7.2 hours; p = 0.16; and 8.2 vs. 11.0 hours; p = 0.007, respectively). Group A had a 
lower cesarean section rate than Group B (7% vs. 30%; p = 0.003), but a higher rate of uterine hyperstimulation
(10% vs. 3%; p = 0.16), tachysystole (17% vs. 3%; p = 0.02), and neonatal admissions to the intensive care unit
within 24 hours of delivery (4 vs. 3; p = 0.71) and after 24 hours (2 vs. 1; p = 0.56) than Group B.
Conclusion: Vaginal misoprostol is more effective than dinoprostone for the elective induction of labor beyond
40 weeks of gestation, but is associated with more uterine hyperstimulation, tachysystole, and neonatal intensive
care unit admissions. [Taiwan J Obstet Gynecol 2010;49(2):151–155]
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induction of labor is complicated, because they have not
been double-blinded [14] and have included both com-
plicated and uncomplicated pregnancies, multiparous
and nulliparous women, and a wide range of gestational
ages (37–42 weeks). Moreover, the risk of side effects
can be reduced by either decreasing the dose of the
drug [12,13] or prolonging the dosage interval [15,16].
Dinoprostone (prostaglandin E2 analogue) and
misoprostol (prostaglandin E1 analogue) are widely
used in “induction of labor” practice for ripening the
cervix and stimulating uterine contractions to achieve
vaginal delivery. Misoprostol has the advantages of
lower cost, no need for refrigeration, and potentially
higher efficacy.
This study compared the efficacy and safety of
vaginal misoprostol (50 μg) with vaginal dinoprostone
(3 mg), both administered at 6-hourly intervals between
repeated doses, in a homogeneous cohort of full-term
pregnancies (nulliparous women with an unfavorable
cervix, gestational age > 40 weeks and < 42 weeks, with
no pregnancy complications). Obstetric and neonatal
outcome measures were assessed. The primary out-
come measures were time from induction to onset of
uterine contractions, time from induction to delivery,
and mode of delivery. The secondary outcomes were
the cesarean section (CS) rate, and the incidences of
meconium-stained amniotic fluid, uterine tachysystole,
and fetal/neonatal complications.
Materials and Methods
This study was conducted between July 1, 2005 and
August 31, 2006. A total of 120 women were selected
for the study. All were recruited at Bahawal Victoria
Hospital, Bahawalpur, Pakistan, a 1,300-bed tertiary
referral center with an average annual delivery rate of
2,500. The hospital board of directors and research eth-
ical committee approved the study, and all participants
gave their written informed consent after the purpose
of the study had been explained to them.
Inclusion criteria were age > 20 years, nulliparity,
accurate dating of gestation, viable singleton pregnancy,
gestational age > 40 weeks and < 42 weeks, cephalic
presentation, unfavorable cervical status defined as a
Bishop score < 6, intact membranes, and patient height
> 150 cm. Exclusion criteria were known contraindica-
tions to receiving prostaglandins, placenta previa, pre-
vious uterine surgery, and any antenatal complications
(medical/obstetric).
A detailed history was obtained for each subject,
along with the results of general physical examinations,
including vital signs and abdominal examination. Fetal
cardiotocography was used to confirm fetal well-being.
A digital examination was also performed. Baseline in-
vestigations included complete blood and urine exami-
nations, blood grouping, and Rh factor determination.
Gestational age was estimated by ultrasound bi-
ometry (via crown-rump length measurements in the
first trimester of pregnancy) in cases where there was
more than 3 days’ difference from the age obtained
because of the last menstrual period [17]. Uterine
tachysystole was defined as more than five contrac-
tions of moderate-to-severe intensity per 10 minutes,
uterine hypertonus as one contraction lasting more
than 2 minutes, and presence of fetal heart rate and
hyperstimulation syndrome as the presence of a non-
reassuring fetal heart rate tracing combined with
either tachysystole or hypertonus [18].
Patients were randomly divided into two groups:
Group A (n = 60) and Group B (n = 60). Group A were
induced with misoprostol, and Group B with dinopro-
stone. The randomization procedure was done by open-
ing sequentially numbered opaque envelopes containing
cards stating the drug to be used. Bishop score was
assessed prior to administration of either preparation;
if it was < 6, then labor induction using either miso-
prostol or dinoprostone was planned.
Fifty micrograms of misoprostol (200-μg tablet,
quartered; Group A) or 3 mg dinoprostone (Group B)
was placed digitally high in the posterior vaginal fornix.
This was repeated at 6-hourly intervals, up to a maxi-
mum of three doses (if needed). Doses were repeated
if there was no uterine activity, or if the uterine con-
tractions were less than two mild contractions in 10
minutes, with the patient being comfortable. Fetal car-
diotocography was performed before each dose to
confirm fetal well-being.
Vaginal assessment was performed when uterine
activity suggested the onset of labor, and the woman
was moved to the labor ward. Maternal vital signs were
monitored at 4-hourly intervals throughout the proce-
dure. The time when significant uterine contractions
started was noted (significant uterine contractions:
3–5 contractions of moderate-to-severe intensity in 10
minutes). Adequate analgesia was given with pethidine.
Continuous fetal and maternal monitoring was per-
formed, and a detailed record of the labor was main-
tained on a partogram.
Failed induction of labor was defined as vaginal deliv-
ery not achieved within 24 hours of initiating induction
[19]. The indications for CS were failed induction,
uncontrolled hyperstimulation or fetal distress. Any
complications occurring during the induction proce-
dure were recorded and managed accordingly. At the
time of delivery, a pediatrician was called to examine
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and resuscitate the baby in the delivery room. Further
management of neonates was carried out accordingly.
Data were analyzed using SPSS version 10 (SPSS
Inc., Chicago, IL, USA) and subjected to descriptive
analysis. Student t tests were applied to measured data
(intervals between induction and significant uterine con-
tractions and delivery). Categorical data were analyzed
using χ2 tests. A p value < 0.05 was considered to be
significant.
Results
Of the 120 study subjects, 78 (65%) were < 25 years
old and the remainder were > 25 years old. The mean
age in Group A was 23 years, while that in Group B
was 25 years. In Group A, 18 (30%) subjects went into
active labor after insertion of a single dose, compared
with only eight (14%) in Group B. The obstetric out-
comes of the subjects are presented in Table 1. The
mean time from induction to onset of significant uter-
ine contractions was 6.1 hours in Group A and 7.2
hours in Group B (p = 0.16). Similarly, the mean time
from induction to delivery was 8.2 hours in Group A
and 11.0 hours in Group B (p = 0.007). Induction failed
in 18 subjects (30%) in Group B, but only failed in two
(3%) in Group A (p < 0.001). Group A had a lower
cesarean section rate than Group B (7% vs. 30%; p =
0.003) (Table 1).
Regarding the modes of delivery, 42 women (70%)
in Group A had spontaneous vaginal deliveries, 14 (23%)
had instrumental vaginal deliveries, and four (6%) re-
quired CS. In Group B, only 26 (43%) delivered vaginally,
while 16 (27%) required instrumental vaginal deliveries
and 18 (30%) required CS (overall p = 0.002).
Table 2 presents the neonatal outcomes. There were
more neonatal admissions to the intensive care unit in
the misoprostol group than in the dinoprostone group
within 24 hours of delivery (4 vs. 3; p = 0.71) and after
24 hours (2 vs. 1; p = 0.56; Table 2).
Discussion
Labor induction is increasingly common [20,21]. Re-
cent studies have shown that this is mainly due to an
increase in inductions performed for marginal or elec-
tive reasons. Elective induction and induction for post-
date pregnancies, often applied to gestations of 40–41
weeks, are common indications [1,21]. Women may
experience distress when labor has not started by the
expected date [22], and obstetricians have to endure
pressure from these patients, as well as the temptation
to use prostaglandins earlier. Suitable evaluation of the
pregnancy and consultation with the patient will iden-
tify those who can benefit from labor induction, thus
eliminating the risk of postmaturity of the fetus, with-
out inducing fetal distress during labor.
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Table 1. Obstetric outcomes*
Variables
Group A Group B 
p
(misoprostol; n = 60) (dinoprostone; n = 60)
Prostaglandin doses for active labor
Single 18 (30) 8 (13) 0.049
Two 36 (60) 38 (63) 0.82
Three 6 (10) 14 (23) 0.07
Interval (hr)
Induction to onset of SUC 6.1 ± 0.6 7.2 ± 0.5 0.16
Induction to delivery 8.2 ± 0.8 11.0 ± 0.7 0.007
Induction to delivery interval detail
< 6 hr 20 (33) 6 (10) 0.006
6–12 hr 32 (53) 30 (50) 0.80
> 12 hr 8 (13) 24 (40) 0.005
Induction failure, n (%) 2 (3) 18 (30) < 0.001
Cesarean section rate, n (%) 4 (7) 18 (30) 0.003
Complications
Uterine hyperstimulation 6 (10) 2 (3) 0.16
Uterine tachysystole 10 (17) 2 (3) 0.02
Allergic reaction 2 (3) 2 (3) > 0.99
Meconium-stained liquor 4 (7) 2 (3) 0.41
*Data are presented as n (%) or mean ± standard error. SUC = significant uterine contractions (3–5 moderate-to-severe contractions in 10 minutes).
The present study compared the use of misoprostol
and dinoprostone for labor induction in a homogeneous
cohort of nulliparous women with intact membranes,
who were all at > 40 weeks’ gestation, with no antenatal
complications. Misoprostol was more effective than
dinoprostone in these carefully selected patients at
shortening not only the time between labor induction
and onset of uterine contractions, but also that between
induction and delivery. This positive result was achieved
with a very low CS rate. This could have clinical implica-
tions in terms of patient health and cost effectiveness.
Meta-analyses published by the Cochrane Library [12]
and by Sanchez-Ramos et al [23] found lower rates of
CS with misoprostol compared with dinoprostone.
Although misoprostol resulted in a higher rate of
uterine hyperstimulation (10%) compared with dinopro-
stone (3%), the difference was not significant; however,
there was a significantly higher incidence of tachysys-
tole with misoprostol. The rate of meconium-stained
liquor during induction with misoprostol use was low,
but was still double that seen with dinoprostone (7%
vs. 3%). The Cochrane meta-analysis [12] also found 
increased likelihoods of meconium staining of amniotic
fluid and uterine tachysystole with misoprostol. Unfa-
vorable neonatal outcomes such as low Apgar score in
the first minute and entry to the neonatal unit within
the first 24 hours were more frequent with misoprostol,
although the differences were not significant. Thus,
although the sample size in this study was too small to
conclusively determine its safety, misoprostol use ap-
pears to be associated with a higher chance of admit-
tance to the neonatal unit within 24 hours than
dinoprostone, even in the absence of asphyxia. These
results emphasize that early induction of childbirth is
not necessarily advisable.
Based on the results of this and previous studies
[13,24,25], the increase in clinically pertinent adverse
effects with misoprostol appears to be dose and dose-
interval dependent. These studies indicate that misopros-
tol not only acts more effectively on the myometrium
than on the cervix, but that a higher dose is needed to
ripen the cervix. This suggests that increasing the inter-
val between repeated misoprostol doses should reduce
the risk of asynchrony between a well- or even hyper-
stimulated uterus and a still not fully ripened cervix.
Misoprostol may exhibit large interpatient variability in
terms of its pharmacokinetics, but it is probable that a
dose of 50 μg might induce asynchrony between efface-
ment of the immature cervix and uterine contractions,
resulting in a more rapid but also more stressful labor.
Based on these findings, we propose that the misopros-
tol dose used in the current study should be slightly
modified. An initial lower dose of misoprostol (20–25μg)
administered at longer intervals should be considered,
with the aim of priming the cervix without inducing
such high uterine contractility.
In conclusion, 50 μg misoprostol administered at
6-hourly intervals is more effective in promoting cervical
ripening and inducing labor than dinoprostone. How-
ever, administration of this drug requires continuous
monitoring because of the possibility of complications,
and its effects on certain aspects of fetal well-being
during labor induction remain to be clarified.
Future studies are needed to compare the efficacy
and safety of different doses of vaginally inserted
misoprostol tablets with those of controlled-release
vaginal misoprostol inserts. Other studies to compare
the efficacy and safety of different doses of controlled-
release vaginal misoprostol inserts are also highly 
recommended [26].
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Table 2. Neonatal outcomes*
Variables
Group A Group B 
p
(misoprostol; n = 60) (dinoprostone; n = 60)
Birth weight (g) 3,165 ± 430 3,273 ± 390 0.15
Perinatal death 0 (0) 1 (2) 0.32
Manual bag-valve-mask ventilation 7 (12) 6 (10) 0.78
Intubations in labor room 1 (2) 1 (2) > 0.99
Apgar score < 7
1 min 10 (17) 5 (8) 0.20
5 min 1 (2) 0 0.32
Birth trauma† 0 (0) 1 (2) 0.32
ICU admissions
Within 24 hr 4 (7) 3 (5) 0.71
After 24 hr 2 (3) 1 (2) 0.56
*Data are presented as n (%) or mean ± standard deviation; †clavicle fractures. ICU = intensive care unit.
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